OGT Opens New Cambridge R&D Site

Oxford Gene Technology (OGT), A Sysmex Group Company, has opened its new facility in Cambridge, UK, in the Cambridge Science Park. The new facility has state-of-the-art refitted laboratories and is approximately three times the size of the company’s previous site.

OGT acquired fluorescence in situ hybridisation (FISH) probe manufacturer Cytocell in February 2014. Since then the company has grown its portfolio, including launching the FDA-cleared in vitro diagnostic (IVD) FISH probe range for AML (Acute myeloid Leukaemia) and MDS (Myelodysplastic syndromes). The number of employees based in Cambridge has increased from 30 to 53 and continues to grow. The expanded operations will support increased volume of product manufacture and shipment. In addition, OGT plans to create a training and demonstration facility where customers can benefit from the company’s FISH expertise.

John Anson, chief executive officer of OGT said, "We are thrilled to celebrate the opening of our state-of-the-art facility in the heart of the Cambridge life science hub. OGT continues to perform well with sustained growth and this investment by Sysmex will accelerate our next phase of product development and global expansion."

Also, Sysmex plans to set up a global R&D facility within the OGT laboratories - similar to other sites in Hamburg and Chicago. This facility will evaluate new technologies in the life sciences field and pursue collaborations with key opinion leaders, in an effort to bring innovative new products to the market. The facility will also be a hub for networking within the life sciences community, Cambridge University and global healthcare companies.

Register as Visitor to CPhI China 2019 NOW!

-----------------------------------------------------------------------
Editor's Note:

If you have any suggestion to the content, 

please email: Julia.Zhang@ubmsinoexpo.com